Pharmaceutical giant AstraZeneca has agreed to sell the US and Canadian rights to its Zoladex cancer treatment drug to American peer TerSera for 250 million US dollars (£200 million). AstraZeneca will also receive quarterly payments based on sales, and will be paid up to 70 million US dollars (£56 million) more based on sales-based milestones. The injectable drug is used to treat prostate cancer, breast cancer and some benign gynaecological disorders. It was first approved for use in the US and Canada in 1989.